Retatrutide Results and the 25% Finding

A phase 3 trial of retatrutide reported a mean body-weight change of 25.0% at 80 weeks in its 12 mg group, compared with 3.9% with placebo. The result is substantial, yet it is a result from a defined trial population, not a personal forecast or a treatment instruction. Our retatrutide reference page explains its investigational status.^[1]

The 25% result came from TRIUMPH-1

The new paper reports TRIUMPH-1, a randomized, double-blind phase 3 trial in adults with obesity who did not have diabetes. Researchers assigned 2,339 participants to once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, or to placebo, for 80 weeks. Randomized means participants were allocated by chance; double-blind means participants and investigators did not know the assigned treatment during the trial.^[1]

Mean weight change was 17.6% in the 4 mg group, 23.7% in the 9 mg group, and 25.0% in the 12 mg group. The placebo group had a mean change of 3.9%. Those figures describe group averages under the study conditions. They do not establish what any individual person will lose or tolerate outside the trial. Readers looking for the broader drug background can start with the retatrutide overview.^[1]

Why retatrutide is called a triple agonist

Retatrutide acts on receptors for GIP, GLP-1, and glucagon. A receptor is a cell protein that responds to a chemical signal. That three-target design separates retatrutide from medicines that act on GLP-1 alone and from dual GIP and GLP-1 agonists such as tirzepatide. Readers who want background on the GLP-1 part of that biology can also read our semaglutide explainer. The new phase 3 paper identifies all three receptor targets, but the result does not show which target accounts for a particular amount of weight change.^[1]

Earlier evidence already suggested that the medicine could produce large average weight changes. In a 48-week phase 2 trial, the 12 mg group had a mean change of 24.2%, compared with 2.1% with placebo. The phase 2 report also described gastrointestinal adverse events as the most common events and noted dose-related changes in heart rate that peaked at 24 weeks before declining.^[2]

How to read the result

The phase 3 report also assessed knee osteoarthritis pain in a subgroup and apnea-hypopnea events in a subgroup with obstructive sleep apnea. Those are measured outcomes within those defined subgroups. They are not evidence that retatrutide is appropriate for every person with joint pain, sleep apnea, or obesity.^[1]

Safety needs the same careful reading. The paper reports gastrointestinal adverse events as the most common events. A trial finding can describe what occurred among enrolled participants under a study protocol. It cannot replace an individual clinical assessment, especially for people with existing conditions or medicines that were not represented in the trial population.^[1]

The headline figure is the 25.0% mean change in the 12 mg group. The paper reports a 21.0 percentage-point difference between that group and placebo. This is a comparison within the trial, with the same 80-week follow-up and the same randomized study design for the groups being compared. It is more useful than treating the 25% figure as a standalone promise. The source report supplies the study population, assignment method, endpoint, and comparator that give the number its meaning.^[1]

The authors used an intention-to-treat approach for weight-related end points. In plain English, that approach analyzes people in the groups to which they were assigned, rather than limiting the analysis to people who completed treatment exactly as planned. It keeps the comparison tied to the randomized groups. The paper explains how it handled treatment changes for the weight analysis.^[1]

What we do not yet know

Eighty weeks is a meaningful follow-up period, though it is not a lifetime answer about benefit, safety, or what happens after treatment stops. The report does not turn a group mean into a guarantee, and it does not settle how the medicine will perform in populations outside its eligibility criteria. Readers should also keep regulatory status separate from trial results. See the retatrutide regulation overview for the site's jurisdiction-specific reference. The retatrutide information page keeps the trial discussion connected to that status context.^[1]

The BMJ reported the phase 3 finding on October 1, 2026, using the same up-to-25% framing. The primary paper supplies the trial design, participant count, outcomes, and adverse-event description. Readers can use that report when a headline is circulating faster than the full results.^[3]

Why this matters

The result gives readers a concrete new phase 3 data point for an investigational triple agonist. It does not provide a reason to seek unregulated products or to self-direct use. For background on a related dual agonist, read our tirzepatide page. If you are considering treatment for obesity or related conditions, discuss the evidence, available approved options, and your own risks with a qualified healthcare professional.^[1]